Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: Results from the SEARCH database

Christopher J. Keto, William J. Aronson, Martha K. Terris, Joseph C. Presti, Christopher J. Kane, Christopher Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: A prostate-specific antigen (PSA) level

Original languageEnglish (US)
Pages (from-to)620-627
Number of pages8
JournalEuropean Urology
Volume65
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Prostate-Specific Antigen
Androgens
Prostatic Neoplasms
Databases
Therapeutics

Keywords

  • Androgen-deprivation therapy
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Urology

Cite this

Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes : Results from the SEARCH database. / Keto, Christopher J.; Aronson, William J.; Terris, Martha K.; Presti, Joseph C.; Kane, Christopher J.; Amling, Christopher; Freedland, Stephen J.

In: European Urology, Vol. 65, No. 3, 03.2014, p. 620-627.

Research output: Contribution to journalArticle

Keto, Christopher J. ; Aronson, William J. ; Terris, Martha K. ; Presti, Joseph C. ; Kane, Christopher J. ; Amling, Christopher ; Freedland, Stephen J. / Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes : Results from the SEARCH database. In: European Urology. 2014 ; Vol. 65, No. 3. pp. 620-627.
@article{85707ded60ab4cfc84dc37d622e48eae,
title = "Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: Results from the SEARCH database",
abstract = "Background: A prostate-specific antigen (PSA) level",
keywords = "Androgen-deprivation therapy, Prostate cancer, Prostate-specific antigen",
author = "Keto, {Christopher J.} and Aronson, {William J.} and Terris, {Martha K.} and Presti, {Joseph C.} and Kane, {Christopher J.} and Christopher Amling and Freedland, {Stephen J.}",
year = "2014",
month = "3",
doi = "10.1016/j.eururo.2012.11.052",
language = "English (US)",
volume = "65",
pages = "620--627",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes

T2 - Results from the SEARCH database

AU - Keto, Christopher J.

AU - Aronson, William J.

AU - Terris, Martha K.

AU - Presti, Joseph C.

AU - Kane, Christopher J.

AU - Amling, Christopher

AU - Freedland, Stephen J.

PY - 2014/3

Y1 - 2014/3

N2 - Background: A prostate-specific antigen (PSA) level

AB - Background: A prostate-specific antigen (PSA) level

KW - Androgen-deprivation therapy

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84895061392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895061392&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.11.052

DO - 10.1016/j.eururo.2012.11.052

M3 - Article

C2 - 23245686

AN - SCOPUS:84895061392

VL - 65

SP - 620

EP - 627

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -